{"In": [0], "an": [1], "interim": [2], "analysis": [3, 74], "of": [4, 11, 46, 58, 65, 71, 75], "this": [5], "phase": [6], "3": [7], "trial,": [8], "the": [9, 44, 55, 72], "addition": [10], "pembrolizumab": [12], "to": [13], "chemotherapy": [14, 21], "resulted": [15], "in": [16], "longer": [17], "progression-free": [18], "survival": [19, 77], "than": [20], "alone": [22], "among": [23], "patients": [24], "with": [25, 38], "advanced": [26], "triple-negative": [27], "breast": [28], "cancer": [29], "whose": [30], "tumors": [31], "expressed": [32], "programmed": [33], "death": [34], "ligand": [35], "1": [36], "(PD-L1)": [37], "a": [39], "combined": [40], "positive": [41], "score": [42], "(CPS;": [43], "number": [45, 57], "PD-L1\u2013staining": [47], "tumor": [48, 60], "cells,": [49, 61], "lymphocytes,": [50], "and": [51], "macrophages,": [52], "divided": [53], "by": [54, 63], "total": [56], "viable": [59], "multiplied": [62], "100)": [64], "10": [66], "or": [67], "more.": [68], "The": [69], "results": [70], "final": [73], "overall": [76], "have": [78], "not": [79], "been": [80], "reported.": [81]}